Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]
GB | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 3, 22 | -0.47
Increased by
0.00%
|
-0.46
Decreased by
-2.17%
|
Aug 4, 22 | -0.46
Increased by
+2.13%
|
-0.42
Decreased by
-9.52%
|
May 5, 22 | -0.41
Increased by
+22.64%
|
-0.48
Increased by
+14.58%
|
Mar 10, 22 | -0.51
Increased by
+38.55%
|
-0.46
Decreased by
-10.87%
|
Nov 3, 21 | -0.47
Increased by
+34.72%
|
-0.51
Increased by
+7.84%
|
Aug 5, 21 | -0.47
Increased by
+24.19%
|
-0.50
Increased by
+6.00%
|
May 6, 21 | -0.53
Increased by
+11.67%
|
-0.60
Increased by
+11.67%
|
Mar 4, 21 | -0.83
Increased by
+1.19%
|
-0.77
Decreased by
-7.79%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 2.37 M
Increased by
+N/A%
|
-42.77 M
Decreased by
-25.82%
|
Decreased by
-1.81 K%
Decreased by
N/A%
|
Jun 30, 22 | 0.00
Decreased by
-100.00%
|
-42.06 M
Decreased by
-26.79%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 0.00
Decreased by
-100.00%
|
-37.06 M
Decreased by
-11.41%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 21 | 823.00 K
Increased by
+N/A%
|
-41.67 M
Increased by
+2.79%
|
Decreased by
-5.06 K%
Decreased by
N/A%
|
Sep 30, 21 | 0.00
Decreased by
-100.00%
|
-33.99 M
Increased by
+8.91%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 21 | 1.51 M
Increased by
+414.33%
|
-33.17 M
Decreased by
-3.52%
|
Decreased by
-2.20 K%
Increased by
+79.87%
|
Mar 31, 21 | 269.00 K
Decreased by
-20.41%
|
-33.27 M
Decreased by
-11.36%
|
Decreased by
-12.37 K%
Decreased by
-39.92%
|
Dec 31, 20 | 0.00
Decreased by
-100.00%
|
-42.86 M
Decreased by
-4.68%
|
Decreased by
N/A%
Decreased by
N/A%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.